SBI Securities
CRDL icon

SBI Securities’s Cardiol Therapeutics CRDL Stock Holding History

SBI Securities’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$770 Sell
464
-27
-5% -$43 ﹤0.01% 2960
2026
Q2 		$520 Buy
491
+16
+3% +$20 ﹤0.01% 3021
2026
Q1 		$641 Hold
475
– – ﹤0.01% 2802
2025
Q4 		$453 Sell
475
-1
-0.2% -$1 ﹤0.01% 2904
2025
Q3 		$509 Sell
476
-1
-0.2% -$1 ﹤0.01% 2953
2025
Q2 		$649 Buy
477
+2
+0.4% +$2 ﹤0.01% 2854
2025
Q1 		$461 Buy
475
+200
+73% +$246 ﹤0.01% 2902
2024
Q4 		$352 Buy
+275
New +$464 ﹤0.01% 3021

Other funds holding CRDL

Tejara Capital
Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return
Integrity Alliance
Integrity Alliance Urbandale, Iowa $3.28B AUM 15.79% 1-Year Est. Return
PVG Asset Management
PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $200B AUM 30.19% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
MGO One Seven
MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Marble Harbor Investment Counsel
Marble Harbor Investment Counsel Boston, Massachusetts $1.02B AUM 15.73% 1-Year Est. Return
Boyer Financial Services
Boyer Financial Services Newport Beach, California $125M AUM 9.98% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return

SBI Securities's CRDL Position: Q3 2026 in Review

SBI Securities reduced its Cardiol Therapeutics (CRDL) stake by 5.5% in Q3 2026, selling an estimated $43 and leaving 464 shares worth $770. The position accounts for ﹤0.01% of the portfolio, ranked #2960.

SBI Securities first reported a position in CRDL in Q4 2024 and has held it in 8 quarters since. 28 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

  • SBI Securities held 464 shares of Cardiol Therapeutics worth $770 as of Q3 2026.
  • SBI Securities sold 27 Cardiol Therapeutics shares in Q3 2026, an estimated $43.
  • Cardiol Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #2960 holding.
  • SBI Securities first reported a position in Cardiol Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • 28 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.